Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial

Lancet

Volumn 347, Issue 9007, 1996, Pages 995-999

  Cuschieri, A ^a,f   Fayers, P ^b   Fielding, J ^c   Craven, J ^d   Bancewicz, J ^e   Joypaul, V ^a   Cook, P ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d Kingstown General Hospital   (Jamaica)

^e HOPE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; PANCREAS RESECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPLENECTOMY; STOMACH CANCER; SURGICAL MORTALITY;

EID: 0029940782     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90144-0     Document Type: Article

References (14)

1. Cancer Statistics: registrations. England and Wales. London: MH Stationery Office, 1989.
2. Allum WH, Powell DJ, McConkey CC, Fielding JWL. Gastric cancer. A 25 year review. Br J Surg 1989; 76: 535-40.
3. Miwa K. Cancer of the stomach in Japan. Gann Monogr Cancer Res 1979; 22: 61-75.
4. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery and its limits of radicality. World J Surg 1987; 11: 418-26.
5. Nakajima T, Nishi M. Surgery and adjuvant chemotherapy for gastric cancer. Hepatogastroenterology 1989; 36: 79-85.
6. Bonenkamp JJ, Van de Velde CJH, Kampschoer GHM, et al. A comparison of factors influencing the prognosis of Japanese and Western gastric cancer patients. World J Surg 1993; 17: 410-15.
7. Kajitani T. Japanese Research Society for the Study of Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Jap J Surg 1981; 11: 127-45.
8. Diggory MT, Cuschieri A. R2/3 gastrectomy for gastric carcinoma: an audited experience of a consecutive series. Br J Surg 1985; 72: 146-48.
9. Smith JW, Shiu MH, Kelsey L, Brennan MF. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 1991; 126: 1469-73.
10. Roder JD, Böttcher K, Siewert JR, et al. Prognostic factors in gastric carcinoma: results of the German Gastric Carcinoma Study 1992. Cancer 1993; 72: 2089-97.
11. Sue-Ling HM, Johnston D, Martin IG, Dixon MF, et al. Gastric cancer: a curable disease in Britain. BMJ 1993; 307: 591-96.
12. Bonenkamp JJ, Songun J, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-48.
13. Yoshino K, Ogawa S, Tanaka T, et al. Controversy regarding extended lymphadenectomy for gastric cancer. In: Nishi M, Sugano H, Takahasi T, eds. International Gastric Cancer Congress Bologna: 1995: vol I, 91-95.
14. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609-16.